Evidence map›Paper›PMID 25926798›Full record

ArticleFrontiers in pharmacology2015

Education and training for medicines development, regulation, and clinical research in emerging countries.

Sandor Kerpel-Fronius, Bernd Rosenkranz, Elizabeth Allen, Rolf Bass, Jacques D Mainard, Alex Dodoo, Dominique J Dubois, Mandisa Hela, Steven Kern, Joao Massud and 2 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sandor Kerpel-FroniusDepartment of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University , Budapest, Hungary.
Bernd RosenkranzDivision of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch University , Cape Town, South Africa ; Fundisa African Academy of Medicines Development, Cape Town , South Africa.
Elizabeth AllenDivision of Clinical Pharmacology, Department of Medicine, South African Faculty, Global Health Network, University of Cape Town , Cape Town, South Africa.
Rolf BassUniversity of Basel, Pharmaceutical Medicine , Basel, Switzerland.
Jacques D MainardMinistry of Higher Education and Research, Institut National de la Santé et de la Recherche Médicale , Paris, France.
Alex DodooWHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical School , Accra, Ghana.
Dominique J DuboisPostgraduate Programme in Pharmaceutical Medicine and Medicines Development Sciences, Université Libre de Bruxelles , Brussels, Belgium.
Mandisa HelaMedicines Control Council, Pretoria , South Africa.
Steven KernQuantitative Sciences, Bill & Melinda Gates Foundation , Seattle, WA, USA.
Joao MassudEducation and Research Institute, Hospital Sirio-Libanes , Sao Paulo, Brazil.
Honorio SilvaBioPharma Educational Initiative, Rutgers University School of Health Related Professions , Newark, NJ, USA ; Inter American Foundation for Clinical Research , New York, NY, USA.
Jeremy WhittySchool of Health Sciences, Hibernia College , Dublin, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this satellite workshop held at the 17th World Congress of Basic and Clinical Pharmacology (WCP2014) was to discuss the needs, optimal methods and practical approaches for extending education and teaching of medicines development, regulation, and clinical research to Low and Middle Income Countries (LMICs). It was generally agreed that, for efficiently treating the rapidly growing number of patients suffering from non-communicable diseases, modern drug therapy has to become available more widely and with a shorter time lag in these countries. To achieve this goal many additional experts working in medicines development, regulation, and clinical research have to be trained in parallel. The competence-oriented educational programs designed within the framework of the European Innovative Medicine Initiative-PharmaTrain (IMI-PhT) project were developed with the purpose to cover these interconnected fields. In addition, the programs can be easily adapted to the various local needs, primarily due to their modular architecture and well defined learning outcomes. Furthermore, the program is accompanied by stringent quality assurance standards which are essential for providing internationally accepted certificates. Effective cooperation between international and local experts and organizations, the involvement of the industry, health care centers and governments is essential for successful education. The initiative should also support the development of professional networks able to manage complex health care strategies. In addition it should help establish cooperation between neighboring countries for jointly managing clinical trials, as well as complex regulatory and ethical issues.

Indexed as

clinical trialscompetencieslearning outcomeslow and middle income countriespharmaceutical medicineregulatory agencies

Identifiers

PMID25926798
PMCPMC4396384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.